Research and Innovation For Addressing Pregnancy Related Concerns and Prenatal Care
As the Pregnancy Company, we view it as our role to demonstrate tangible meaning from scientific innovation. Behind each of our tests is an expectant mother vigilantly protecting her baby, a healthcare practitioner seeking to build fortresses around her patients, and an unborn baby with a lifetime of unbridled potential.
We remain focused on delivering pivotal and actionable information to pregnant women, their physicians, and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs.
Scientific Rigor for the Sake of Moms and Babies
Our testing process seeks to uphold the highest level of quality. We are a Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited, and New York State approved laboratory performing the PreTRM Test for all 50 U.S. states. Our quality systems and processes meet regulatory requirements and professional standards for testing.
When Neonatal Health Improves, We All Benefit
By identifying pregnancies that are at higher risk for a premature delivery, we’re able to offer patients and their providers the potential to intervene and improve outcomes. Reducing NICU admissions and length-of-stay, in addition to reductions in morbidity and mortality rates, can have tremendous emotional and financial benefit to families, healthcare providers, employers, and payers.
The Future of Our Proprietary Technology Platform
As a leader in proteomic test development and validation, advanced bioinformatics, and multidimensional data analysis, we are committed to improving neonatal health by providing early and accurate risk predictors of pregnancy complications. In addition to our available PreTRM Test, we’re continuing to develop a robust pipeline of novel blood-based biomarker tests designed to uniquely address unmet needs in pregnancy related concerns. This enhanced risk predictor detection may provide patients and physicians with earlier opportunities for interventional treatment.
Potential future applications of our proteomic and bioinformatics technology platform may include:
Fetal Growth Restriction
Together, We Can Do Better
Revolutionizing prenatal care delivery requires team effort.
Our strategic partnerships provide the surround-sound expertise the task requires.
Our latest publications
Stay up-to-date on the latest content from Sera
- Branch, et al. Prediction and Prevention of Preterm Birth. Am J Perinatol. 2021. DOI https://doi.org/ 10.1055/s-0041-1732339.
- Grabner M, et al. Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction. Clinicoecon Outcomes Res. 2021.